PF-Atlas › Drugs › TERT Gene Therapy

TERT Gene Therapy

Idiopathic Pulmonary Fibrosis · AAV-TERT restores telomere length in AEC2s — addresses genetic root cause

Mechanism
AAV-TERT restores telomere length in AEC2s — addresses genetic root cause
Development stage
Preclinical→Phase I
Evidence level
Level 3 (Preclinical)
Developer
Telomere Therapeutics

Overview

TERT/TERC mutations in ~8-15% sporadic IPF and 25% familial IPF. Strongest genetic association of any common lung disease.

Explore related

Treatment profileAAV-TERT restores telomere length in AEC2s — addresses genetic root causeAll trialsResearch
Medical disclaimer. This page summarizes research about TERT Gene Therapy for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.